Accolade, Inc. (NASDAQ:ACCD) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Accolade, Inc. (NASDAQ:ACCD) have earned a consensus recommendation of “Hold” from the fourteen research firms that are covering the company, Marketbeat Ratings reports. Thirteen investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.51.

A number of equities research analysts recently issued reports on the stock. Truist Financial cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Piper Sandler lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. William Blair cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Stifel Nicolaus restated a “hold” rating and set a $7.03 price target (down from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Accolade in a research report on Wednesday, January 8th.

Hedge Funds Weigh In On Accolade

Large investors have recently made changes to their positions in the company. Mission Creek Capital Partners Inc. acquired a new stake in Accolade in the third quarter worth about $38,000. Laird Norton Wetherby Trust Company LLC bought a new position in shares of Accolade in the 4th quarter valued at about $38,000. Pallas Capital Advisors LLC bought a new position in shares of Accolade in the 4th quarter valued at about $38,000. Boothbay Fund Management LLC acquired a new stake in shares of Accolade during the 4th quarter worth approximately $43,000. Finally, Wolverine Trading LLC bought a new stake in shares of Accolade during the third quarter worth approximately $51,000. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Stock Down 0.1 %

Shares of ACCD opened at $6.99 on Monday. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average price of $6.94 and a two-hundred day moving average price of $4.97. The stock has a market cap of $573.13 million, a price-to-earnings ratio of -3.11 and a beta of 2.18. Accolade has a 12 month low of $3.08 and a 12 month high of $10.45.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. Equities analysts predict that Accolade will post -1.2 EPS for the current fiscal year.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.